Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TYK Medicines, Inc
浙江同源康醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)

VOLUNTARY ANNOUNCEMENT
FURTHER INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CHAIRMAN, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

This announcement is made by TYK Medicines, Inc (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to the voluntary announcements of the Company dated September 8, 2026 and September 10, 2026. Dr. WU Yusheng ("**Dr. Wu**"), the chairman, executive director and chief executive officer of the Company, has informed the Company that he expects to further purchase shares of the Company on the open market. It is currently expected that the total amount of this increase in shareholding will not exceed HK$2 million. Dr. Wu has undertaken to the Company that the shares of the Company acquired by him through the increase in shareholding during the next one month will each be subject to a voluntary lock-up period of six months from the respective date of purchase, during which he will not sell or otherwise transfer the relevant shares. Dr. Wu has stated that the acquisition of such shares is funded by his own financial resources. The increase in shareholding demonstrates his firm belief and strong confidence in the future development prospects of the Group.

Based on the information available to the Company and as far as the board of directors is aware, following the increase in Dr. Wu's shareholding in the Company and as at the date of this announcement, the Company has continued to maintain sufficient public float of the issued shares in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and the increase in shareholding has been conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules.

By Order of the Board of Directors
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, November 22, 2026

As at the date of this announcement, the board of directors comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.